First-line treatment of acute ocular toxoplasmosis
Acute ocular toxoplasmosis — toxoplasmic retinochoroiditis — is a sight-threatening intraocular infection that requires prompt, structured treatment. This page summarises the evidence-based first-line approach; the full protocol detail is available via the link below.
Treatment approach
First-line management involves a combination regimen of antimicrobial agents together with corticosteroids, sustained over several weeks. In cases where the central retinal zone is involved, additional local ocular therapy may be indicated alongside systemic treatment. The specific agents, sequencing, dosing, and indications for adjunctive therapy are set out in the full protocol.
Clinical goal
Achieve resolution of the active retinochoroidal lesion.
Target: resolution within 1–2 months
References
DOI: 10.1007/s10792-021-01994-9
- The treatment of ocular toxoplasmosis includes both antimicrobial drugs and corticosteroids (topical and oral) and is maintained for 4–6 weeks.
- The first choices include one of the following combination regimens: (1) pyrimethamine, sulfadiazine, folinic acid and prednisone; (2) pyrimethamine, clindamycin, folinic acid and prednisone; (3) pyrimethamine, sulfadiazine, clindamycin, folinic acid and prednisone.
- Corticosteroids are usually initiated 3 days after the start of antibiotic therapy and must be suspended at least 10 days before the antimicrobial drugs.
- Intravitreal treatment may also be necessary in cases with fovea involvement or active lesion(s) within zone 1 as an adjunctive to systemic therapy.
- Typically, toxoplasmic retinochoroiditis in immunocompetent patients is expected to resolve within 1 to 2 months.
View source ↗